FDA Advisory Panel Recommends Multi-Cancer Blood Test
An FDA advisory panel has recommended approval for a blood test that can detect up to 50 forms of cancer. The test, called Galleri, is developed by the company Grail.
The FDA advisory panel, composed of independent experts, reviewed the evidence for the Galleri blood test and decided to recommend it for approval. The test is designed to detect up to 50 forms of cancer through a single blood draw. According to Grail, the company behind the test, Galleri has the potential to identify cancer in its early stages, when it is more treatable. The panel's recommendation is a significant step towards making the test available to the public. The FDA will now review the panel's recommendation and make a final decision on whether to approve the test. If approved, the Galleri test could become a valuable tool in the early detection and treatment of cancer. The test's ability to detect multiple forms of cancer could also help reduce the number of unnecessary tests and procedures. Grail's development of the Galleri test is a notable advancement in the field of cancer detection. The company's work on the test has been ongoing, and the panel's recommendation marks a major milestone in the test's journey towards potential approval. The FDA's final decision on the test is expected to be made in the coming months.
The Galleri test uses a complex algorithm to analyze the blood sample and identify potential cancer biomarkers. The test is not intended to be a replacement for traditional cancer screening methods, but rather a complementary tool to aid in early detection. Grail has conducted extensive research on the test, including clinical trials, to demonstrate its safety and effectiveness.
Go Deeper
What types of cancer can the Galleri test detect?
The Galleri test can detect up to 50 forms of cancer, although the exact types of cancer it can detect have not been fully disclosed. The test is designed to identify cancer biomarkers in the blood, which can indicate the presence of cancer.
How does the Galleri test work?
The Galleri test uses a complex algorithm to analyze a blood sample and identify potential cancer biomarkers. The test is designed to detect tiny fragments of DNA that are shed by cancer cells into the bloodstream.
What is the next step for the Galleri test?
The FDA will now review the advisory panel's recommendation and make a final decision on whether to approve the test. If approved, the test could become available to the public in the coming months.
Is the Galleri test a replacement for traditional cancer screening methods?
No, the Galleri test is not intended to be a replacement for traditional cancer screening methods. Rather, it is designed to be a complementary tool to aid in early detection.
What are the potential benefits of the Galleri test?
The potential benefits of the Galleri test include earlier detection of cancer, which can improve treatment outcomes. The test could also help reduce the number of unnecessary tests and procedures, which can be costly and invasive.
More health
Medicare Drug Plan Deductible Limit Rises to $700 in 2027; Enrollment Ends December 7
Medicare's standard drug coverage numbers rise in 2027, with the deductible limit moving to $700 and the yearly out-of-pocket cap to $2,400, though wh
Nov 14health50+4.3 Million People Must Replace a Medicare Plan That Ends This Year
KFF, using federal plan files, says 4.3 million people will lose a Medicare Advantage drug plan or a stand-alone drug plan at the end of 2026. Open en
Nov 12health50+Study Links a Common Bone Medicine to a Lower Dementia Risk
Research from the University of Hong Kong, shared widely by ScienceDaily on November 9, found that older adults with weak bones who took a common bone
Nov 11